[144] Dianthus Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. (DNTH) Form 144 notifies the SEC of a proposed sale of 20,000 shares of common stock acquired on 09/09/2025 via exercise of stock options from the issuer. The filer lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker, with an approximate aggregate market value of $636,000.00 and that the company has 32,188,345 shares outstanding. The notice indicates the shares were to be paid for in cash on the same acquisition date and that there were no reported sales by the seller in the prior three months. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Insider plans to sell 20,000 shares acquired by option exercise; transaction is disclosed via Form 144.

The filing documents a proposed sale of common stock resulting from an option exercise on the same day as acquisition. The broker is identified and the aggregate market value is provided. The filing reports no other sales in the prior three months and includes the signed certification regarding material non-public information. The disclosure satisfies Rule 144 notice requirements but by itself contains no operational or financial performance information.

Corporate Governance Expert

TL;DR: Routine Form 144 filing for sale following option exercise with required attestations.

The document is a routine compliance notice under Rule 144 indicating the intention to sell 20,000 shares through a named broker and confirming payment in cash. It includes the standard attestation about material information and shows no other reported sales in the prior three months. The filing does not disclose the identity of the selling person beyond the required fields, nor any trading plan adoption date.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20000	636000.00	32188345	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2025	Exercise of Stock Options	Issuer			20000	09/09/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What transaction does the Dianthus Therapeutics (DNTH) Form 144 report?

The Form 144 reports a proposed sale of 20,000 shares of common stock acquired by exercise of stock options on 09/09/2025.

Who is the broker named in the DNTH Form 144 filing?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, 8th Floor, New York, NY 10004.

What is the aggregate market value and shares outstanding reported?

The filing lists an aggregate market value of $636,000.00 for the 20,000 shares and 32,188,345 shares outstanding.

Were any shares sold by the same person in the prior three months according to the filing?

The filing states Nothing to Report for securities sold during the past three months.

How were the acquired shares paid for in the DNTH Form 144?

The payment method is listed as cash, with payment dated 09/09/2025.

Does the filing indicate any undisclosed material information?

The filer makes the standard representation that they do not know of any material adverse information about the issuer that has not been publicly disclosed.